对黑色素瘤进行个体化治疗的基因组分析。
Analysis of the genome to personalize therapy for melanoma.
机构信息
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Oncogene. 2010 Oct 14;29(41):5545-55. doi: 10.1038/onc.2010.323. Epub 2010 Aug 9.
Abstract
The treatment of cancer is being revolutionized by an improved understanding of the genetic events that occur in tumors. Advances in the understanding of the prevalence and patterns of mutations in melanoma have recently led to impressive results in trials of personalized, targeted therapies for this disease. In this review, we will discuss the molecular targets that have been validated clinically, additional genetic events that are candidates for future trials, and the challenges that remain to improve outcomes further in this aggressive disease.
摘要
通过对肿瘤中发生的遗传事件的深入了解，癌症的治疗正在发生革命性的变化。最近，对黑色素瘤中突变的普遍性和模式的认识的提高，导致了针对这种疾病的个体化靶向治疗试验中令人瞩目的结果。在这篇综述中，我们将讨论已经在临床上得到验证的分子靶点、有潜力成为未来试验候选的其他遗传事件，以及在这种侵袭性疾病中进一步提高治疗效果所面临的挑战。
相似文献
1
Analysis of the genome to personalize therapy for melanoma.对黑色素瘤进行个体化治疗的基因组分析。
Oncogene. 2010 Oct 14;29(41):5545-55. doi: 10.1038/onc.2010.323. Epub 2010 Aug 9.
2
[Therapeutic approaches in Melanoma - a paradigm for personalized medicine].[黑色素瘤的治疗方法——个性化医疗的范例]
Praxis (Bern 1994). 2012 Jul 25;101(15):955-9. doi: 10.1024/1661-8157/a001005.
3
Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases.原发性食管黑色素瘤的基因异常：10 例系列中 c-KIT、PDGFR、KRAS、NRAS 和 BRAF 的分子分析。
Mod Pathol. 2011 Apr;24(4):495-501. doi: 10.1038/modpathol.2010.220. Epub 2010 Dec 3.
4
KIT Suppresses BRAF-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling.KIT通过减弱致癌性RAS/MAPK信号传导来抑制BRAF突变型黑色素瘤。
Cancer Res. 2017 Nov 1;77(21):5820-5830. doi: 10.1158/0008-5472.CAN-17-0473. Epub 2017 Sep 25.
5
Targeted therapy for melanoma: a primer.黑色素瘤的靶向治疗：入门指南。
Surg Oncol Clin N Am. 2011 Jan;20(1):165-80. doi: 10.1016/j.soc.2010.09.003.
6
Molecular biology of melanoma.黑色素瘤的分子生物学。
J Am Acad Dermatol. 2012 Nov;67(5):1049-54. doi: 10.1016/j.jaad.2011.06.047. Epub 2012 Mar 28.
7
Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.迈向恶性黑色素瘤患者的个体化治疗：BRAF 突变生物学的分子见解。
Future Oncol. 2013 Feb;9(2):245-53. doi: 10.2217/fon.12.179.
8
Molecular profiling of melanoma and the evolution of patient-specific therapy.黑色素瘤的分子分析与个体化治疗的演进。
Semin Oncol. 2011 Apr;38(2):236-42. doi: 10.1053/j.seminoncol.2011.01.004.
9
Ras, Raf, and MAP kinase in melanoma.Ras、Raf 和 MAP 激酶在黑色素瘤中的作用。
Adv Anat Pathol. 2013 Jul;20(4):217-26. doi: 10.1097/PAP.0b013e3182976c94.
10
BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.日本黑色素瘤患者中BRAF、KIT和NRAS突变以及c-KIT、磷酸化细胞外信号调节激酶和磷酸化AKT的表达
J Dermatol. 2015 May;42(5):477-84. doi: 10.1111/1346-8138.12822. Epub 2015 Mar 13.
引用本文的文献
1
Clinical implications and molecular mechanism of long noncoding RNA LINC00518 and protein-coding genes in skin cutaneous melanoma by genome‑wide investigation.通过全基因组研究探讨长链非编码RNA LINC00518和蛋白质编码基因在皮肤黑色素瘤中的临床意义及分子机制
Arch Dermatol Res. 2025 Feb 22;317(1):454. doi: 10.1007/s00403-025-03961-1.
2
Targeting Cancer Hallmarks Using Selected Food Bioactive Compounds: Potentials for Preventive and Therapeutic Strategies.利用选定的食物生物活性化合物靶向癌症标志：预防和治疗策略的潜力
Foods. 2024 Aug 26;13(17):2687. doi: 10.3390/foods13172687.
3
Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling.恶性黑色素瘤：概述、新观点及维生素D信号传导
Cancers (Basel). 2024 Jun 18;16(12):2262. doi: 10.3390/cancers16122262.
4
Personalized tumor combination therapy optimization using the single-cell transcriptome.基于单细胞转录组的个体化肿瘤联合治疗优化。
Genome Med. 2023 Dec 1;15(1):105. doi: 10.1186/s13073-023-01256-6.
5
Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1.临床实践指南：分子肿瘤标志物，第 2 版，综述第 1 部分。
Int J Clin Oncol. 2024 Jan;29(1):1-19. doi: 10.1007/s10147-023-02430-x. Epub 2023 Nov 29.
6
Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer.染色体不稳定作为乳腺癌的促成特征和核心标志
Breast Cancer (Dove Med Press). 2023 Mar 9;15:189-211. doi: 10.2147/BCTT.S383759. eCollection 2023.
7
Pan-Cancer landscape of protein activities identifies drivers of signalling dysregulation and patient survival.泛癌种蛋白活性全景分析揭示信号失调的驱动因素和患者生存情况。
Mol Syst Biol. 2023 Mar 9;19(3):e10631. doi: 10.15252/msb.202110631. Epub 2023 Jan 23.
8
Minimally Invasive Skin Transcriptome Extraction Using a Dermal Biomarker Patch.使用真皮生物标志物贴片进行微创皮肤转录组提取
Dermatol Ther (Heidelb). 2022 Jun;12(6):1313-1323. doi: 10.1007/s13555-022-00733-x. Epub 2022 Apr 30.
9
RNAi in (Hemiptera: Pentatomidae): Transcriptome Assembly for the Development of Pest Control Strategies.半翅目（异翅亚目：蝽科）中的RNA干扰：用于制定害虫防治策略的转录组组装
Front Plant Sci. 2022 Apr 1;13:804839. doi: 10.3389/fpls.2022.804839. eCollection 2022.
10
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.BRAF 加 MEK 抑制剂在 BRAF V600 突变肿瘤中的组织非特异性活性。
Mol Cancer Ther. 2022 Jun 1;21(6):871-878. doi: 10.1158/1535-7163.MCT-21-0950.
本文引用的文献
1
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.持续肿瘤生长需要暂时存在的慢循环黑素瘤细胞亚群。
Cell. 2010 May 14;141(4):583-94. doi: 10.1016/j.cell.2010.04.020.
2
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).转录通路特征可预测 MEK 依赖性及对 selumetinib（AZD6244）的反应。
Cancer Res. 2010 Mar 15;70(6):2264-73. doi: 10.1158/0008-5472.CAN-09-1577. Epub 2010 Mar 9.
3
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.PLX4032，一种选择性 BRAF(V600E) 激酶抑制剂，激活 ERK 通路，增强 BRAF 黑色素瘤细胞的迁移和增殖。
Pigment Cell Melanoma Res. 2010 Apr;23(2):190-200. doi: 10.1111/j.1755-148X.2010.00685.x. Epub 2010 Feb 10.
4
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.激酶失活的 BRAF 和致癌性的 RAS 通过 CRAF 合作驱动肿瘤进展。
Cell. 2010 Jan 22;140(2):209-21. doi: 10.1016/j.cell.2009.12.040.
5
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.RAF 抑制剂使野生型 RAF 激活 MAPK 通路并增强其生长。
Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.
6
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.KIT 基因突变在源于与慢性和间歇性阳光暴露相关解剖部位的黑色素瘤中发生的频率较低。
Pigment Cell Melanoma Res. 2010 Apr;23(2):210-5. doi: 10.1111/j.1755-148X.2010.00671.x. Epub 2010 Jan 20.
7
The PI3K pathway as drug target in human cancer.PI3K 通路作为人类癌症的药物靶点。
J Clin Oncol. 2010 Feb 20;28(6):1075-83. doi: 10.1200/JCO.2009.25.3641. Epub 2010 Jan 19.
8
Melanoma from bench to bedside: meeting report from the 6th international melanoma congress.黑色素瘤：从实验室到临床——第六届国际黑色素瘤大会会议报告
Pigment Cell Melanoma Res. 2010 Feb;23(1):14-26. doi: 10.1111/j.1755-148X.2009.00655.x. Epub 2009 Dec 17.
9
A comprehensive catalogue of somatic mutations from a human cancer genome.一个人类癌症基因组中体细胞突变的综合目录。
Nature. 2010 Jan 14;463(7278):191-6. doi: 10.1038/nature08658. Epub 2009 Dec 16.
10
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.转移性黑色素瘤中AKT激活的综合分子与临床分析
Clin Cancer Res. 2009 Dec 15;15(24):7538-7546. doi: 10.1158/1078-0432.CCR-09-1985.
Zotero 插件